<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00417105</url>
  </required_header>
  <id_info>
    <org_study_id>NHD001</org_study_id>
    <nct_id>NCT00417105</nct_id>
  </id_info>
  <brief_title>Protein-Bound Uremic Retention Solutes in Long Nocturnal Hemodialysis</brief_title>
  <official_title>A Multicentric Observational Study on the Removal of Protein-Bound Uremic Retention Solutes in Nocturnal Hemodialysis: A Cross-Sectional Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although remarkable progress has been made, chronic kidney disease still poses a major burden
      on both individual patients, as well as on society as a whole. There is a strong inverse
      relationship between decreasing renal function, as estimated by glomerular filtration rate,
      and mortality rate, especially death due to cardiovascular disease. The exact cause(s) remain
      to be elucidated. Uremic toxins might play an important role.

      In the course of decreasing renal function the concentration of numerous intracellular and
      extracellular compounds vary from the non-uremic state. But still increasing number of uremic
      retention solutes are being identified. Renal replacement strategies aim to remove
      potentially harmful substances from the body. Traditionally much attention has been paid to
      small water-soluble molecules such as urea nitrogen and creatinine. Based on the results of
      the recent HEMO and ADEMEX studies, increases of small water-soluble solute removal above the
      level reached with modern dialysis techniques - hemodialysis, peritoneal dialysis (HD, PD) -
      seem not to be advantageous with regard to patient outcome. These findings may point to the
      importance of other distinct groups of uremic retention solutes. In view of the data
      described above, protein-bound solutes might be good candidates.

      Several advantages of long duration hemodialysis have been observed, including a better
      control of blood pressure by decreasing extracellular fluid volume, lowering peripheral
      vascular resistance and improving endothelium-dependent and -independent vasodilation. A
      normalization of heart rate variability and improvement of left-ventricular function was
      noted as well. Furthermore, anemia control has been shown to be easier and several
      nutritional parameters improved in patients treated with long duration HD. The therapy
      results in higher small water-soluble solute removal, phosphate removal and greater
      elimination of larger molecules (e.g. β2-microglobulin).

      It seems an appealing question whether a better control of the serum levels of protein-bound
      solutes can be achieved by long duration (nocturnal) hemodialysis. This might be another
      advantage of this therapeutic modality, or may even in part explain the better outcome of
      patients treated this way.

      The study compares intermittent hemodialysis with long nocturnal hemodialysis with respect to
      serum concentrations of several protein bound uremic toxins, as well as solute removal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>removal of protein-bound retention solutes</measure>
    <time_frame>1 dialysis session</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>hemodialysis twice weekly 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>nocturnal dialysis twice weekly 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>nocturnal hemodialysis, 8 hours every other night</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>nocturnal hemodialysis, 8 hours, six times per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hemodialysis</intervention_name>
    <description>group 1: twice weekly, four hours</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hemodialysis</intervention_name>
    <description>group 2: twice weekly, eight hours</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hemodialysis</intervention_name>
    <description>group 3: every other day, eight hours</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hemodialysis</intervention_name>
    <description>group 4: six days a week, eight hours</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, urine, dialysate
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Maintenance hemodialysis patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Maintenance hemodialysis (&gt; 3 months duration)

          -  Informed consent

        Exclusion Criteria:

          -  No consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Björn KI Meijers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pieter Evenepoel, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Dejagere, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virga Jesse Ziekenhuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nigel Toussaint, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geelong Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virga Jesse Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 2006 Mar;69(6):1081-7.</citation>
    <PMID>16421516</PMID>
  </reference>
  <reference>
    <citation>Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis. 2002 Aug;40(2):339-47.</citation>
    <PMID>12148107</PMID>
  </reference>
  <reference>
    <citation>Pierratos A. Daily nocturnal home hemodialysis. Kidney Int. 2004 May;65(5):1975-86.</citation>
    <PMID>15086951</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2006</study_first_submitted>
  <study_first_submitted_qc>December 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2006</study_first_posted>
  <last_update_submitted>March 4, 2009</last_update_submitted>
  <last_update_submitted_qc>March 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pieter Evenepoel</name_title>
    <organization>University Hospitals Leuven</organization>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>dialysis adequacy</keyword>
  <keyword>chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

